134 related articles for article (PubMed ID: 9737787)
21. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
22. Molecular prognostic markers in breast cancer.
Dahiya R; Deng G
Breast Cancer Res Treat; 1998; 52(1-3):185-200. PubMed ID: 10066082
[TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors.
Tong D; Kucera E; Schuster E; Schmutzler RK; Swoboda H; Reinthaller A; Leodolter S; Zeillinger R
Int J Cancer; 2000 Oct; 88(2):319-22. PubMed ID: 11004687
[No Abstract] [Full Text] [Related]
24. BRCA1 and BRCA2 gene mutations in hereditary and sporadic ovarian cancer and the clinical implications.
Farghaly SA
Am J Obstet Gynecol; 1998 Oct; 179(4):1101-2. PubMed ID: 9790407
[No Abstract] [Full Text] [Related]
25. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma.
Katsama A; Sourvinos G; Zachos G; Spandidos DA
Cancer Lett; 2000 Mar; 150(2):165-70. PubMed ID: 10704738
[TBL] [Abstract][Full Text] [Related]
26. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Hanby AM; Kelsell DP; Potts HW; Gillett CE; Bishop DT; Spurr NK; Barnes DM
Int J Cancer; 2000 Oct; 88(2):204-8. PubMed ID: 11004669
[TBL] [Abstract][Full Text] [Related]
27. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer.
Sigbjörnsdottir BI; Ragnarsson G; Agnarsson BA; Huiping C; Barkardottir RB; Egilsson V; Ingvarsson S
J Med Genet; 2000 May; 37(5):342-7. PubMed ID: 10807692
[TBL] [Abstract][Full Text] [Related]
28. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
[TBL] [Abstract][Full Text] [Related]
29. Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer M; Berns EM
Mol Cell Endocrinol; 1999 Sep; 155(1-2):143-52. PubMed ID: 10580847
[TBL] [Abstract][Full Text] [Related]
30. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
Sessa F; Solcia E; Capella C; Bonato M; Scarpa A; Zamboni G; Pellegata NS; Ranzani GN; Rickaert F; Klöppel G
Virchows Arch; 1994; 425(4):357-67. PubMed ID: 7820300
[TBL] [Abstract][Full Text] [Related]
31. Differences between hereditary and sporadic ovarian cancer.
Zweemer RP; Verheijen RH; Menko FH; Gille JJ; van Diest PJ; Coebergh JW; Shaw PA; Jacobs IJ; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):151-3. PubMed ID: 10206407
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences.
Chiaravalli AM; Furlan D; Facco C; Tibiletti MG; Dionigi A; Casati B; Albarello L; Riva C; Capella C
Virchows Arch; 2001 Jan; 438(1):39-48. PubMed ID: 11213834
[TBL] [Abstract][Full Text] [Related]
33. [Recent developments in the molecular genetic understanding of ovarian carcinoma].
Shimizu Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():489-95. PubMed ID: 15535294
[No Abstract] [Full Text] [Related]
34. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
35. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
[TBL] [Abstract][Full Text] [Related]
36. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
37. The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S; Bates V; Lord R; Green JA
Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
[TBL] [Abstract][Full Text] [Related]
38. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
